viewRosetta Genomics Ltd. (USA)

Rosetta Genomics gets U.S. patent for kidney tumor gene expression

The new patent allowance adds to the company's IP protection for its kidney cancer test.

Kidney cancer is among the 10 most common cancers in both men and women in the U.S.

Rosetta Genomics Ltd. (NASDAQ:ROSG) rose in morning trading after the provider of microRNA-based and other molecular diagnostics was granted a U.S. patent allowance for the use of gene expression signature for the classification of kidney tumors.

Shares advanced 12% to $0.950 at 11:40 a.m. in New York.

The U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to “Gene Expression Signature for Classification of Kidney Tumors,” the Rehovot, Israel-based company said in a statement on Monday.

The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).

This U.S. patent allowance complements the intellectual property protection for Rosetta’s kidney cancer test, which is covered in a U.S. patent granted in July of 2015.

The patent is owned jointly with Tel Hashomer Medical Research Ltd., the technology transfer company of the Chaim Sheba Medical Center in Israel.

“This patent allowance expands our leading intellectual property position in microRNA technology, and further protects our mi-KIDNEY sub-classification assay,” CEO Kenneth Berlin said in the statement.

Kidney cancer is among the 10 most common cancers in both men and women with approximately 61,000 new cases of primary kidney tumors and 14,000 deaths per year in the U.S.

Quick facts: Rosetta Genomics Ltd. (USA)

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: XPhyto sees Germany as key market as they announce deal with...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers and Bunker, Managing Director Wolfgang Probst joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with German Brewer Oettinger development, production, and distribution of cannabis-infused beverages and...

2 days, 17 hours ago

2 min read